YAP-mediated mechanotransduction promotes fibrotic activity by Racanelli, Michael
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
6-27-2019 2:00 PM 
YAP-mediated mechanotransduction promotes fibrotic activity 
Michael Racanelli 
The University of Western Ontaro 
Supervisor 
Andrew Leask 
The University of Western Ontario 
Graduate Program in Physiology and Pharmacology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Michael Racanelli 2019 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Skin and Connective Tissue Diseases Commons 
Recommended Citation 
Racanelli, Michael, "YAP-mediated mechanotransduction promotes fibrotic activity" (2019). Electronic 
Thesis and Dissertation Repository. 6283. 
https://ir.lib.uwo.ca/etd/6283 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
ii 
 
Abstract 
Fibrosis, a phenotype associated with mortality for a multitude of diseases, has no 
disease-modifying treatment. We examine if Verteporfin (VP), an inhibitor of the YAP-
TEAD complex, currently in wide clinical use for macular degeneration, can inhibit pro-
fibrotic gene expression in human dermal fibroblasts. Also, an in vivo approach was 
taken using a Pten-deficient mouse of progressive skin fibrosis for examining effects on 
melanoma metastasis. We found that treatment with VP reduced basal expression of a 
variety of profibrotic genes and prevented a myofibroblast-like phenotype in response to 
TGFβ1. Indeed, genome-wide expression analysis suggested that VP inhibited a cluster 
of profibrotic genes with and without added TGFβ1. Preliminary analysis of metastasis to 
the lung of melanoma tumors in Pten-deficient mice showed a trend towards increased 
metastasis the absence of Pten expression by fibroblasts; i.e., in a fibrotic 
microenvironment. My findings support targeting YAP as a potential treatment for 
fibrotic diseases. 
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Summary for Lay Audience 
 Pathological fibrosis is the progressive stiffening of skin or other organs, 
ultimately interfering with organ function and resulting in death. Pathological fibrosis is 
involved with 45% of mortalities in the developed world and has no available treatment. 
Progressive stiffening of the tissue is characterized by the progressive differentiation of 
local cells known as fibroblasts into stiff cells known as myofibroblasts. These cells exert 
mechanical tension onto themselves and the scaffolding around cells known as the 
extracellular matrix. This effect is involved in normal processes such as wound repair, 
however in fibrotic disease, it becomes dysregulated. The progressive increase of tension 
in the tissue also changes gene expression of proteins in the cell. The most well-known 
protein that is produced in cases of fibrotic disease is CCN2. This protein is known to 
bind to the cell surface and is thought to prevent the resolution of cellular stiffness. In 
fact, CCN2 also functions to transition more cells into myofibroblasts and increase tissue 
stiffness, creating a positive-feedback loop. Increased stiffness seen in fibrotic disease 
highly reflects the tumor microenvironment, the scaffolding around cancerous cells, and 
is thought to aid the migration of tumor cells to other locations in the body. Recent 
research has pointed towards YAP as a central mediator of fibrotic gene expression, 
including CCN2. Here, we repurposed Verteporfin, a drug currently on the market for 
macular degeneration, as an inhibitor of YAP. Administering Verteporfin to fibroblasts 
prevented differentiation into myofibroblasts normally induced by TGFβ1. A mass 
analysis of gene expression revealed that inhibiting YAP with Verteporfin reduced 
expression of many known fibrosis-related genes, including CCN2. These findings 
support YAP as a central mediator of fibrosis, and repurposing Verteporfin to inhibit 
YAP could be a viable therapeutic strategy with relatively little financial investment. To 
test the ability of a fibrotic microenvironment to enhance cancer metastasis, we used a 
mouse model with silenced Pten, a cellular signaling protein upstream from Yap in the 
cellular signaling pathway, to induce spontaneous fibrosis. However, the induced fibrotic 
phenotype was not as stiff as expected, and the results were inconclusive. 
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1 Introduction 
1.1 Fibrosis 
Fibrosis, the final pathological outcome of many chronic inflammatory diseases, 
involved with nearly 45% of all deaths in the developed world.  There is no available 
anti-fibrotic treatment that blocks and/or reverses disease progression  (Wynn, 2007; 
Wynn et al., 2012). In normal tissue repair, inflammation occurs in response to injury in 
three distinct phases. The first is an early proinflammatory step, in which the release of 
cytokines recruits neutrophils, monocytes, and other innate immune cells to the site of 
injury. In the second phase, the proinflammatory response begins to subside and key 
inflammatory cells such as macrophages switch to a reparative phenotype. In the final 
step, the inflammatory response is resolved with inflammatory cells exiting the site of 
lesion or are eliminated through apoptosis. (Eming et al., 2017). Wound repair 
macrophages are characterized by the enhanced production of numerous growth factors, 
including platelet derived (PDGF), insulin-like (IGF-1), and vascular endothelial (VEGF-
α), which promote cell proliferation and blood vessel development (Shimokado et al., 
1985; Rappolee et al., 1988; Berse et al., 1992; Chujo et al., 2009; Willenborg et al., 
2012). They also produced transforming growth factor beta one (TGFβ1), which 
stimulates local and recruited fibroblasts into myofibroblasts that facilitate wound 
contraction and closure, as well as the synthesis of extracellular matrix (ECM) 
components (Akhurst et al., 2012). In normal tissue repair, myofibroblasts are resolved 
through apoptosis (Leight et al., 2012), and recruited cells are returned to their original 
state. Production of the ECM is balanced with degradation of the ECM through the action 
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of matrix metalloproteinases (MMPs) (Gill et al., 2008). Pathological fibrosis is 
characterized by the excess deposition of extracellular matrix (ECM) components by 
myofibroblasts, such as collagen and fibronectin, in an organ or tissue. Normal tissue 
repair can turn into an irreversible fibrotic response in cases of severe or repetitive injury, 
or in cases where the wound healing response becomes dysregulated (Wynn et al., 2012). 
Progressive fibrosis results in gradual loss of organ function due to the replacement of 
functional tissue with scar tissue, and is the major cause of morbidity in individuals with 
systemic sclerosis (SSc) (Ho et al., 2014).  
1.2 Systemic sclerosis (SSc) 
Systemic sclerosis (SSc), also referred to as scleroderma, is an auto-immune 
rheumatic disease that is characterized by progressive fibrosis of the skin, internal 
organs and vasculature. Although uncommon, it has high morbidity and mortality. As 
the etiology of SSc fibrosis is unknown, treatment options are limited to those that 
target disease symptoms (Denton et al., 2017). Genome-wide expression profiling of 
SSc skin revealed that the disease is highly heterogeneous, with patients subdivided 
into either “fibroproliferative” or “inflammation/innate immunity” cohorts based on 
the overexpression of genes compared to individuals without SSc (Milano et al., 2008). 
Altered expression of genes associated with transforming growth factor beta (TGFβ) 
and Wnt signaling are commonly seen in fibroblasts cultured from SSc skin biopsy 
samples; these genes appear to be overexpressed in the fibroproliferative cohort of SSc 
patients (Gardner et al., 2006). Sustained, localized inflammation, vascular damage and 
the resultant presence of local and systemic profibrotic growth factors/cytokines facilitate 
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the differentiation of resident fibroblasts (and possibly recruited cells, including 
pericytes, fibrocytes and endothelial/adipogenic progenitor cells) into α-smooth muscle 
actin (SMA)-expressing myofibroblasts. The latter are considered the effector cells of 
fibrosis, which deposit and remodel large quantities of ECM components (Trojanowska, 
2010) (Figure 1.1). Thus, induction of myofibroblasts is also promoted by the increased 
ECM stiffness inherent to the scar tissue, although it is unclear the extent to which ECM 
stiffness acts upstream or in parallel to the effect of growth factors and cytokines on 
fibroblasts.   
1.3 The myofibroblast 
Myofibroblasts, the primary type of cells that produce ECM in response to injury in 
every organ of the body, produce high levels of α-smooth muscle actin (SMA)-containing 
stress fibers, which are highly contractile. These fibers are linked to the surrounding 
ECM through focal adhesions, and transduce mechanical tension from the ECM to the 
myofibroblast (Bissell, 1998; Koivisto et al., 2014; Hinz, 2016). In normal wound repair, 
TGFβ-induced myofibroblasts are resolved through apoptosis or deactivation after wound 
repair is completed. However, should this program persist or be aberrantly activated, 
fibrotic responses result. For example, when endothelial cells are injured, an extra- 
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Figure 1.1 Model of myofibroblast differentiation in fibrotic lesions 
Profibrotic growth factors such as TGFβ1 stimulate differentiation of resident fibroblasts 
into α-SMA expressing myofibroblasts, which display elevated integrin/focal adhesion 
kinase (FAK) mediated extracellular matrix (ECM) contraction. Myofibroblasts 
excessively deposit collagen and other pro-fibrotic components, such as cellular 
communication network factor 2 (CCN2), which stiffen the ECM.  Some pro-fibrotic 
components signal back on other resident fibroblasts to stimulate further myofibroblast 
differentiation and ECM stiffness, thus creating a pro-fibrotic autocrine signaling loop. If 
the production of these mechano-sensitive factors is regulated by YAP, then intervention 
with verteporfin (VP) may break the autocrine pro-fibrotic loop and provide a therapeutic 
benefit.  
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domain A (EDA)-containing isoform of fibronectin is released, which recruits and 
activates progenitor cells that differentiate into myofibroblasts, failing to senesce after the 
initial stimulus is removed (Hutchenreuther et al., 2016). These myofibroblasts then 
excessively deposit and remodel collagen and other ECM components, resulting in 
increased ECM stiffness, which further acts on myofibroblasts. Thus, myofibroblasts are 
maintained by an autocrine, pro-adhesive signaling loop. Supporting this notion, 
myofibroblasts cultured from lesion areas of SSc patients, compared to fibroblasts from 
unaffected areas of SSc patients or with healthy individuals, excessively adhere to and 
contract the ECM (Thannickal et al., 2003; Leask, 2012). Overall, the available data 
suggest that mechanical tension from the ECM acting on the fibroblast may initiate and 
perpetuate the fibrotic phenotype through a process known as mechanotransduction.  
1.4 Integrin β1-mediated mechanotransduction 
Fibroblasts involved in fibrotic lesions develop stronger attachments to the ECM 
through structures called focal adhesions (FAs). These attachments signal through 
clusters of specialized cell-surface receptors called integrins, which stimulate 
differentiation of fibroblast into myofibroblasts (Eckes et al., 2000; Gabbiani, 2003). 
Focal adhesion kinase (FAK) mediated mechanotransduction was shown to be required 
for TGFβ- induced myofibroblast differentiation. This was demonstrated using FAK-
deficient fibroblasts, or using the FAK/src inhibitor PP2 (Liu et al., 2007). We found that 
FAK contributes to the persistent fibrotic phenotype of SSc fibroblasts (Shi-wen et al., 
2012).  Indeed, cell attachment to the ECM and consequent activation of FAK is required 
for myofibroblast differentiation in response to TGFβ1 (Thannickal et al., 2003; Liu et 
 6 
 
al., 2007; Ding et al., 2017). Mechanical tension from the ECM is communicated through 
integrins to the nucleus through SMA-containing stress fibers. Integrins are heterodimers 
composed of one α- and one β- subunit. The main integrins that are involved in adhesion 
to type I collagen include: α1β1, α2β1, and α11β1 (Schiro et al., 1991; Pozzi et al., 1998; 
Carracedo et al., 2010). The integrin subunit β1 is as a key, central mediator of pro-
fibrotic mechanotransduction (Asano et al., 2006; Zhou et al., 2010). Moreover, integrin 
αvβ1 mediates activation of latent TGFβ in response to strain and ECM contraction 
(Leask et al., 2014; Reed et al., 2015).  Partial inhibition of integrin α1β6 prevented 
murine pulmonary fibrosis without exacerbating inflammation (Horan et al., 2008). Thus 
integrin-mediated adhesion may act, depending on the context, in both parallel and 
upstream fashions to promote myofibroblast activity. Mice with fibroblasts that are 
deficient in the integrin β1 subunit are resistant to bleomycin-induced skin fibrosis; 
however, they also show impaired cutaneous tissue repair and progressive skin thinning, 
indicating an essential role for this subunit in dermal homeostasis (Liu et al., 2009, 2010 
a). 
1.5 CCN matricellular proteins 
The cellular communication network (CCN) family of matricellular proteins 
nomenclature was officially designated by the HUGO Gene Nomenclature Committee in 
October 2018 (Perbal et al., 2018). The family contains six matricellular proteins (CCN1 
through 6), each consisting of four conserved cysteine rich domains; an insulin-like 
growth factor-binding domain, a Von Willebrand factor type C domain, a 
thrombospondin type 1 domain and a CT-terminal domain containing a cysteine knot 
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motif (except for CCN5 which lacks a CT domain) (Figure 1.2). These matricellular 
proteins are secreted into the ECM where they have a wide variety of regulatory roles. 
These roles are just recently being elucidated, and are proposed to interact in a dynamic 
spatio-temporal relationship between multiple members of the CCN family and each of 
their four domains (Perbal, 2018). The tetra modular structure of the CCN proteins 
potentially allows for a wide variety of interactions and functions. Either these functions 
overlap or are activated by individual CCN proteins based on the cytokines expressed in 
the specific tissue (Perbal, 2018).  
1.5.1 CCN2  
Formerly known as connective tissue growth factor (CTGF), cellular communication 
network factor 2 (CCN2) was first identified as a protein secreted from human umbilical 
vein endothelial cells (Bradham et al., 1991). Although not usually expressed under 
normal conditions by mesenchymal cells, CCN2 is rapidly induced in fibroblasts in 
response to tissue injury (Igarashi et al., 1993; Kapoor et al., 2008). In an in vivo rabbit 
model of hypertrophic scarring, antisense-mediated degradation of CCN2 mRNA reduced 
excess scarring without significantly affecting wound healing (Sisco et al., 2008).  In 
healthy tissues, CCN2 is essentially absent, however in bleomycin-induced skin fibrosis 
and SSc skin lesions, CCN2 is overexpressed. This suggests CCN2 may be a key 
indicator and mediator of fibrotic injury (Igarashi et al., 1996; Liu et al., 2010 b). 
  
 8 
 
 
 
Figure 1.2 Signaling by CCN family members.  
CCN1, CCN2 and CCN3 bind TGFβ, fibronectin, integrins, LRP1 and HSPGs as 
indicated. CCN proteins appear to signal principally through the C-terminal quarter 
(domain IV) to activate adhesive signaling pathways and hence amplify responses to 
TGFβ or fibronectin. (Reproduced with permission from: All in the CCN family: essential 
matricellular signaling modulators emerge from the bunker (Leask et al., 2006). doi: 
10.1242/jcs.03270)  
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1.5.2 CCN2 signaling pathway 
In response to TGFβ, fibroblasts not only differentiate into myofibroblasts but also 
begin to express CCN2 (Igarashi et al., 1993). TGFβ-induced CCN2 expression occurs 
via the canonical Smad3 pathway; however, the maintenance of the SSc phenotype is 
independent of Smad signaling, as the Smad-binding element in the CCN2 promoter is 
required for TGFβ-induced CCN2 promoter activation, but not for the heightened CCN2 
promoter activity observed in fibroblasts isolated from fibrotic lesions of SSc patients 
(Holmes et al., 2001). CCN2 is expressed in cultured activated myofibroblasts. In a three-
dimensional co-culture system, SSc epidermal cells also increase CCN2 expression 
through interleukin 1 alpha (IL-1α) production and endothelin-1 induced TGFβ 
expression (Aden et al., 2010). CCN2 exists in the ECM where it binds to fibronectin and 
the fibronectin receptor integrins α4, α5, β1, as well as syndecan-4. Fibroblast attachment 
to CCN2 also requires MEK/ERK activity (Holmes et al., 2001). CCN2-deficient 
myofibroblasts showed reduced activation via FAK/Akt signaling pathways (Shi-wen et 
al., 2006), suggesting that CCN2 may be a fibrogenic marker or mediator. 
1.5.3 CCN2 and progressive fibrosis 
Use of immunohistochemical and specific ELISA assays has shown that CCN2 
protein expression levels correlate with the progression of SSc and pulmonary fibrosis; 
possibly indicating that CCN2 is a key regulator in the un-resolving progressive nature of 
fibrotic disease (Sato et al., 2000). More specifically, levels of the amino-terminal half of 
CCN2 in plasma and dermal interstitial fluid of SSc patients correlate with the severity of 
the disease (Dziadzio et al., 2005). Even more importantly, in a transient fibrotic mouse 
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model induced by TGFβ, addition of CCN2 caused the fibrotic lesion to persist. More 
specifically, although subcutaneous injection of TGFβ resulted in the formation of 
granulation tissue, this fibrotic response was transient, and disappeared after cessation of 
application of ligand, despite 7 days of consecutive injections. However injection of 
TGFβ1 combined with CCN2 produced a sustained fibrotic response that persisted for at 
least 14 days and after cessation of ligand injection (Mori et al., 1999). Thus, CCN2 
presents itself as a possible target for therapeutic intervention to interfere with the 
progressiveness of SSc, without harming normal fibrogenesis.  
Recently, we generated a conditional knockout model that allowed for the direct 
testing of whether expression of CCN2 is required for fibrosis. We used a transient 
bleomycin model and a progressive fibrosis model involving a fibroblast-specific deletion 
of the adhesive signaling suppressor Pten; the fibrotic phenotype seen in both models of 
skin fibrosis were rescued by a fibroblast-specific deletion of Ccn2 (Liu et al., 2011, 2013 
a). Moreover, targeting CCN2 using a monoclonal antibody partially blocked 
TGFβ/CCN2-induced skin fibrosis in mice (Ikawa et al., 2008). Similarly, CCN2 
expression is essential for fibrotic models in other organs (Morales et al., 2013; Dorn et 
al., 2018; Petrosino et al., 2019). FG-3019,  a humanized monoclonal anti-CCN2 
targeting antibody which has been under development for ~15 years, has been tested on 
mice and showed to block angiotensin II-induced skin fibrosis. (Makino et al., 2017). The 
anti-fibrotic effects of FG-3019 was also beneficial in three other murine fibrotic models; 
a multiorgan fibrosis model through intraperitoneal injections of CCN2 and TGFβ2, the 
unilateral uretal obstruction renal fibrosis model, and an intratracheal bleomycin-induced 
pulmonary fibrosis (Wang et al., 2011). When tested in phase 2 human clinical trials on 
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idiopathic pulmonary fibrosis (IPF), results on a small number of patients suggested that 
FG-3019 could slow disease progression (Raghu et al., 2016). Investigation into the 
control of CCN2 expression may yield an alternative strategy to blocking CCN2 
expression. A small molecule inhibitor may be able to penetrate tissue better than a large 
antibody and therefore may prove to be an effective therapy. 
1.6 YAP/TAZ/TEAD 
Yes-associated protein 1 (YAP) and TAZ are mechanosensitive transcriptional co-
activators known for regulating the Hippo signalling pathway to control organ size and 
tumorigenesis (Huang et al., 2005). YAP/TAZ bind to the TEA domain (TEAD) family 
of transcription factors to co-activate gene transcription (Vassilev et al., 2001). Recently, 
YAP has been shown to be a downstream regulator of fibroblast activation and 
mechanotransduction in physiological and pathological fibrosis (Liu et al., 2015; Piersma 
et al., 2015; Mohri et al., 2017; Rinschen et al., 2017). Furthermore, YAP regulation of 
mechanotransduction was shown to involve integrins (Elbediwy et al., 2016). 
Visudyne© (VP for injection) is an approved drug currently used in the treatment of 
macular degeneration. The drug is injected intravenously and photoactivated in the eye. 
Interestingly, the non-photoinduced molecular form of VP has been shown to inhibit 
YAP activation, with no significant cytotoxicity in human trabecular meshwork cells 
below 2 µM (Chen et al., 2015). Thus, YAP presents itself as a possible target for 
therapeutic intervention.CCN2 expression is stimulated by an active YAP/TAZ/TEAD 
transcription factor complex (Quan et al., 2014). Indeed, we were the first group to 
demonstrate the involvement of YAP/TEAD in promoting CCN gene expression (Leask 
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et al., 2003). Chromatin immunoprecipitation experiments confirmed that TEAD and 
YAP bound the CCN2 promoter (Zhao et al., 2008). Indeed, CCN2 expression can be 
used as a readout of activation of the YAP/Hippo pathway (Yang et al., 2018). In human 
keratinocytes, knockdown of YAP significantly reduced expression of both CCN1 and 
CCN2 (Quan et al., 2014). Thus, a potential non-canonical mechanotransduction 
signalling loop emerges, where YAP-mediated CCN2 expression induces stiffening of the 
ECM, which further stimulates expression of CCN2 (Figure 1.3). Overexpression of 
YAP-mediated CCN2 through the pro-adhesive signaling loop can have severe effects not 
only in fibrotic disease, but other diseases as well, as seen in many types of cancer. 
1.7 Fibrosis and cancer metastasis 
As early as 1998, the CCN family of proteins was linked to cancer and its 
progression, as recombinant CCN1 protein was found to promote angiogenesis and tumor 
growth (Babic et al., 1998). Later, both CCN1 and CCN2 were discovered to be 
expressed in primary tumors and the stromal fibroblasts within the fibrotic tumor stroma 
(Rachfal et al., 2004). In fact, CCN1 and CCN2 are overexpressed in many types of 
cancer, and have been linked to tumor progression and metastasis (Xie et al., 2004; 
Pickles et al., 2007). Indeed, formation of a fibrotic tumor microenvironment is induced 
by CCN2, reflecting stiffening of the ECM in fibrosis. Integrin-mediated ECM stiffening, 
collagen crosslinking, and formation of FAs were found to enhance breast tumorigenesis 
(Levental et al., 2009). Interestingly, there is also evidence that CCN2 and YAP/TAZ are 
drivers of cancer metastasis (Shimo et al., 2006; Deng et al., 2007; Warren et al., 2018). 
We found that CCN2 expression by tumor stroma is required for melanoma metastasis 
(Hutchenreuther et al., 2015). An in vitro YAP or TAZ knockdown strongly reduced the  
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Figure 1.3 Proposed fibrotic signaling feedback loop.  
Membrane bound integrin heterodimers composed of α5/11β1 subunits bind mechanically 
active ECM components such as CCN2, which activates Src/FAK signaling and PI3K. 
This activates YAP downstream and translocates it to the nucleus, stimulating expression 
of pro-fibrotic genes. ECM components are then secreted from the cell, causing further 
stiffening of the ECM and further activation of integrin receptors. 
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expression of CCN2, and the ability of these transfected melanoma cells to form lung 
metastases in mice following tail injection (Nallet-Staub et al., 2014).  
In addition to the involvement of a fibrotic microenvironment in tumorigenesis and 
tumor metastasis, there is also evidence that it favors chemotherapy resistance. Activation 
of integrin β4 on mammary malignant epithelial cells is required for resistance to 
apoptosis (Weaver et al., 2002). Melanoma caused by the BRAF (V600E) mutation, 
initially susceptible to targeted therapy, commonly develops chemotherapy resistance 
within 6-8 months by a variety of mechanisms, including stimulation of ECM production 
and remodeling via integrin-β1/Src/FAK signaling (Frame et al., 2015; Hirata et al., 2015; 
Taylor et al., 2018).  Indeed, cancer associated fibroblasts (CAFs) are thought to provide 
a safe-haven for melanoma through formation of a stiff ECM. It may be possible that 
migration of cancer cells through the ECM is aided by the stiffness of a fibrotic tumor 
stroma. Primary tumors possibly prime their microenvironment for increased cell motility 
through YAP/TAZ mediated expression of CCN2 to increase matrix stiffness and through 
formation of focal adhesions. Through this it may be possible for cancer cells to invade 
past the basement membrane and move into the blood stream, where they can spread to 
other organs (Figure 1.4).  
Further support for the notion that activated mechanotransduction promotes tumor 
growth and metastasis comes from recent studies showing that YAP/TAZ/TEAD promote 
metastasis for numerous types of cancer, including melanoma, lung cancer, breast cancer, 
cholangiocarcinoma, gastric cancer, ovarian cancer, colorectal cancer, and oral squamous 
cell carcinoma. (Warren et al., 2018). In other regards, invasiveness of melanoma cells 
with an activating BRAF mutation was linked to a loss of adhesive signaling suppressor   
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Figure 1.4 YAP/TAZ activation promotes several steps of the metastatic cascade. 
Depicted are the critical steps in the metastatic cascade. To spread tumor cancer cells 
(brown) undergo an EMT and then must invade through basement membranes and the 
surrounding tissue until they encounter a blood or lymphatic vessel. To intravasate they 
must then invade between endothelial cells (yellow). While in circulation, tumor cells 
interact with immune cells (blue) and platelets (orange). To seed distant organs, cells 
must arrest either by becoming lodged in small capillaries, or through active adhesion to 
the vessel wall, and then successfully exit the vessel (extravasation). To form a metastatic 
tumor, the cancer cell must survive and proliferate in a new microenvironment. Whether 
increased YAP/TAZ activity or decreased Hippo pathway activity promotes each of these 
steps is indicated. The direction of blood flow is indicated by red dotted arrows. (Used 
with open access from Warren et al., 2018 doi: 10.3390/cancers10040115. Copyright © 2018 
by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article 
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distributed under the terms and conditions of the Creative Commons Attribution (CC BY) 
license (http://creativecommons.org/licenses/by/4.0/).) 
 
 
phosphatase and tensin homologue, deleted on chromosome ten (PTEN) (Dankort et al., 
2009). 
1.8 Phosphatase and tensin homologue 
PTEN was first identified as a tumor suppressor frequently lost in a variety of cancers 
including brain, breast, and prostate (Li et al., 1997; Steck et al., 1997) PTEN is a dual 
specificity protein and lipid phosphatase whose primary target is the second messenger 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which it hydrolyzes to 
phosphatidylinositol (4,5)-bisphosphate (PIP2) (Maehama et al., 1998). PTEN also 
blocks phosphatidylinositol 3 kinase (PI3K) by preventing recruitment of AKT 
(Stambolic et al., 1998), which directly interferes with the aforementioned 
mechanotransduction pathway. In glioma cells, PTEN activity is required for cellular 
migration, and there is evidence that this migration is regulated through suppression of 
Src (Raftopoulou et al., 2004; Dey et al., 2008). Furthermore, PTEN has also been 
reported to dephosphorylate FAK, leading to reduced cell migration and focal adhesion 
formation (Tamura et al., 1998) 
PTEN protein expression was notably reduced in diffuse cutaneous SSc fibroblasts, 
consequently phosphorylation of Akt was also elevated (Parapuram et al., 2011). An in 
vivo deletion of Pten, specific to fibroblasts, resulted in spontaneous development of 
progressive dermal fibrosis. Loss of Pten resulted in a 3-fold increase in dermal thickness 
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due to excess deposition of collagen (Parapuram et al., 2011). Furthermore, fibrosis 
caused by loss of Pten in mouse fibroblasts was dependent on Ccn2 expression (Liu et 
al., 2013 a; Parapuram et al., 2014). In these experiments, knockout of Pten or Ccn2 was 
induced specifically in fibroblasts through expression of Cre-ER(T) under a fibroblast-
specific mouse proα2(I)collagen promoter, along with a 6-kb transcriptional enhancer 
located far upstream from the promoter (Zheng et al., 2002; Ramirez et al., 2006). To 
investigate the ability of a fibrotic microenvironment to exacerbate melanoma tumor 
metastasis, we could use the aforementioned Pten-deficient mouse model to induce a 
spontaneous, pathological fibrotic tumor microenvironment, and assess its effect on 
tumor metastasis.  
1.9 Rationale, objective and hypothesis 
Activated mechanotransduction is common in both progressive fibrosis and cancer 
metastasis. It is possible the activated tumor stroma reflects the fibrotic 
microenvironment seen in SSc, and that a stiffened ECM may aid in primary tumor 
metastasis through enhanced pro-adhesive signaling. Verteporfin (VP) has been shown to 
suppress the formation of the YAP-TEAD complex (Feng et al., 2016). This allows us to 
investigate the role of YAP in pro-fibrotic gene regulation and mechanotransduction, 
both in the presence and absence of TGFβ1. I hypothesize that YAP inhibition with VP in 
fibroblasts will decrease expression of pro-fibrotic gene clusters both in the presence and 
absence of TGFβ1, and that an increased fibrotic microenvironment will enhance the 
metastasis of melanoma in vivo. Thus, the objectives for this experiment are as follows: 
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1. Assess the alterations to the transcriptome of a fibroblast due to YAP 
inhibition during TGFβ-induced fibroblast activation. 
2. Assess the effect of an exacerbated fibrotic microenvironment on melanoma 
metastasis using a Pten-deficient in vivo fibrotic model.  
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2 Materials and Methods 
2.1 Cell culture  
Human foreskin fibroblasts (HFFs) were purchased from the ATCC and stored in 
liquid nitrogen. HFFs were thawed and grown in T75 flasks (Fisher Scientific 
Cat#07000229). HFFs were cultured at 37.5 °C and 5% CO2 in high glucose Dulbecco's 
Modified Eagle's Medium (DMEM) (ThermoFisher Cat#11995-073), 10% fetal bovine 
serum (FBS) (Life Technologies Cat#12483-020) and 1% antibiotic/antimycotic solution 
(ThermoFisher Cat#15240-062). Culture medium was replaced every 2-3 days, and cells 
were passaged when reaching 80% confluency. They were rinsed with Dulbecco’s 
phosphate-buffered saline (DPBS) (ThermoFisher Cat#14040182), detached using 
trypsin-EDTA 0.25% (ThermoFisher Cat#25200072) for two minutes, and sub cultured 
onto new flasks with fresh medium. After the tenth passage (P10), HFFs were sub 
cultured again onto 6-well plates and once they reached 80% confluency, they were 
serum-starved by replacing the medium with low glucose DMEM (ThermoFisher 
Cat#11885092) with 0.5% FBS and 1% antibiotic/antimycotic. 
HFFs (P10) were then treated with Verteporfin (VP) (Sigma-Aldrich CAS#129497-
78-5). VP was diluted in dimethylsulfoxide (DMSO) (ThermoFisher Cat#TS-20688) to 
0.5 µg/ml, and cells were treated with either DMSO as a vehicle control or VP (volumes 
of each treatment were equal). Cells were also treated with either VP or DMSO in 
parallel with recombinant human TGFβ1 (R&D Systems Cat#240-B-002) at 1 µg/ml. 
Total treatment time was 6 hours, with TGFβ1 being added 30 minutes after VP. After 
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treatment, the cells were washed with 1 ml DPBS and Trizol was added to begin RNA 
extraction. 
2.2 RNA isolation 
Trizol (Invitrogen cat#15596018) was added, 1 ml per well, plates were scrapped into 
tubes and incubated at room temperature for 5 min. Chloroform (Sigma cat#C2432) was 
added, 0.2 ml for every 1 ml of Trizol. Samples were shaken vigorously for 15 seconds 
and incubated at room temperature for 2-3 min, then were centrifuged at 12,000 RCF for 
15 min at 4°C. The upper aqueous layer was transferred to a separate tube (~450 µl per 1 
ml Trizol), and 0.5 ml of isopropyl alcohol (Sigma cat#I9516) was added to each tube. 
Tubes were inverted 2-4 times and incubated at room temperature for 10 min, followed 
by centrifugation at 12,000 RCF for 15 min at 4°C. Supernatant was discarded and the 
RNA pellet was washed by adding 1 ml ethanol (100%). Tubes were inverted 2 times and 
centrifuged again 12,000 RCF for 7 min at 4°C. The ethanol was removed, and the 
washing step was repeated one more time. Following centrifugation, the pellet was dried 
by removing the ethanol and allowed to air dry. The RNA pellet was dissolved in 30 µl 
UltraPure™ DNase/RNase-Free Distilled Water (cat#10977-023), and frozen at -22°C. 
2.3 qPCR analysis 
RNA concentrations were determined using a NanoDrop 2000/2000c 
Spectrophotometer. To synthesize cDNA, 1 µg of RNA was loaded into 16 µl 
UltraPure™ DNase/RNase-Free Distilled Water, in addition to 4 µl Quanta cDNA 5X 
qScript supermix (VWR cat#CA101414-112). The mixture was inserted into a 
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thermocycler to undergo a polymerase chain reaction (5 min @25°C, 30min @ 42°C, 
5min @ 85°C, held at 4°C) to synthesize cDNA.  
Quanta SYBR master mix (VWR cat#CA101414-284) were made for various genes 
of interest (0.7 µl UltraPure™ DNase/RNase-Free Distilled Water, 5 µl SYBR mix, 0.3 
µl primer, for every 4µl cDNA diluted 1:30, plated on a 384-well plate). Primers were 
selected using Primer-BLAST and purchased from Life Technologies for the following 
targets:  
Gene target Forward primer sequence Reverse primer sequence 
Β-actin CCTCGCCTTTGCCGATCC CGCGGCGATATCATCATCG 
CTGF/CCN2 GAGGAGTGGCTGTGTGACG TCTTCCAGTCGGTAACCGC 
CCN1 CGGCTCCCTGTTTTTGGAAT TTGAGCACTGGGACCATGAA 
COL1A1 CCCCGAGGCTCTGAAGGTC GGAGCACCATTGGCACCTTT 
COL1A2 CCCCCGGTCCTGCTGGAAGT GCCAGGGGGACCAACTGCAC 
TGFβ1 GCCGTGGAGGGGAAATTGAG TGAACCCGTTGATGTCCACTT 
FN1 CTGGCCAGTCCTACAACCAG CGGGAATCTTCTCTGTCAGCC 
aSMA CCGGGACTAAGACGGAATC TTGTCACACACCAAGGCATT 
ITGA5 TGCCGAGTTCACCAAGACTG TGCAATCTGCTCCTGAGTGG 
ITGA11 CTGTGGCCAGGGTTCACG TGTAGCCAAAGAAGGCGGTC 
LRP1 GAGTCTGCTTCGTGTGCCTA CAGTCATTGTCATTGTCGCATCT 
EDN1 AGAAACAGTCTTAGGCGCTGA TGGACTGGGAGTGGGTTTCT 
POSTN TGCCCAGCAGTTTTGCCCAT CGTTGCTCTCCAAACCTCTA 
TNC GCCAATCATTTGAACAAAGCGG CCCCTCCCACTTGACCACTA 
PTEN TGTAAAGCTGGAAAGGGACGA GGAATAGTTACTCCCTTTTTGTCTC 
YAP GAACTCGGCTTCAGGTCCTC AGGGTCAAGCCTTGGGTCTA 
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PCR amplification was conducted with the following heat cycles in a real-time  
thermocycler using ABI7900 software (95°C for 2:00min, [95°C for 0:10min, 60°C for 
0:30min]x40). β-actin was used for reference, CT values from this housekeeping gene 
were used to calculate ∆Ct. Delta-delta CT analysis (∆∆Ct = ∆Ct (treatment) – ∆Ct 
(Control average)) yielded fold-change (Fold gene expression = 2^-(∆∆Ct)) for the 
treatment groups. The data sets were tested using an unpaired t-test/ordinary one-way 
ANOVA (P<0.05) (GraphPad Prism™ 8). 
2.4 Microarray analysis 
Two separate 6-hour treatments of VP (0.5 µg/ml) on HFFs ± TGFβ1 (1µg/ml) were 
performed as described in section 2.1 (n=2). All sample labeling and GeneChip 
processing was performed at the London Regional Genomics Centre (Robarts Research 
Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA quality was assessed using 
the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA) and the RNA 
6000 Nano kit (RIN≥7) (Caliper Life Sciences, Mountain View, CA). Single stranded 
complementary DNA (sscDNA) was synthesized from 100 ng of total RNA, as per the 
Affymetrix GeneChip WT PLUS Reagent Kit 
(http://media.affymetrix.com/support/downloads/manuals/wtplus_reagentkit_assay_manu
al.pdf, Affymetrix, Santa Clara, CA).  Total RNA was first converted to cDNA, followed 
by in vitro transcription to make cRNA. This cRNA was used to synthesize single 
stranded cDNA, and the cRNA was hydrolyzed. 5.5 ug of single stranded cDNA was 
synthesized, end labeled and hybridized, for 16 hours at 45°C to a Human Gene 2.0 ST 
array. All liquid handling steps were performed by a GeneChip Fluidics Station 450 and 
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GeneChips were scanned with the GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, 
CA) using Command Console v3.2.4. 
Probe level (.CEL file) data were generated using Affymetrix Command Console 
v3.2.4. Probes were summarized to gene level data in Partek Genomics Suite v6.6 
(Partek, St. Louis, MO) using the RMA algorithm (Irizarry et al., 2003).  Partek software 
was used to determine gene level ANOVA p-values and fold changes. A Fisher’s exact 
test was used to create p-values for GO and KEGG Pathway enrichment. Gene level 
ANOVA data input into Transcriptome Analysis Console 4.0.1 software (ThermoFisher) 
were filtered by fold-change values to compare gene lists between different treatments. 
2.5 Genotyping 
DNA was extracted from an ear notch boiled in an acidic solution (25mM 
NaOH/0.2mM EDTA) and then neutralized (40mM Tris-HCL). Genotype was 
determined through polymerase chain reaction followed by gel electrophoresis. Primers 
and amplification conditions were as follows: Cre700 forward: 
ATCCGAAAAGAAAACGTTGA reverse: ATCCAGGTTACGGATATAGT (94.0/5:00, 
[94.0/0:45, 55.0/0:30, 72/1:00]x35 cycles, 72/7:00), yielding amplicons 500kb in size. 
Pten forward: ACTCAAGGCAGGGATGAGC reverse 1: 
AATCTAGGGCCTCTTGTGCC reverse 2: GCTTGATATCGAATTCCTGCAGC 
(94.0/1:00, [94.0/0:30, 55.0/0:30, 72.0/1:40]x35, 72/7:00)(Lesche et al., 2002). 
Fragments were resolved on 1% agarose gels and visualized with ethidium bromide. 
Further qPCR analysis to compare Pten expression between Ptenfl/fl + corn oil and Ptenfl/fl 
+ tamoxifen groups was performed as described in section 2.3 using the following Pten 
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primer (F: ACCAGAGACAAAAAGGGAGTCACAA R: 
CGGGTCTGTAATCCAGGTGATTTT).  
2.6 Generation of fibroblast specific Pten deficient 
mice 
Mice hemizygous for tamoxifen-dependent Cre recombinase under the control of a 
fibroblast-specific promoter-enhancer cassette from the proα2(I) collagen gene (Zheng et 
al., 2002) were bred with mice homozygous for floxed Pten alleles to generate mice 
heterozygous for floxed Pten and hemizygous Cre. These mice were bred another 
generation to generate the desired genotype: hemizygous Cre and homozygous for floxed 
Pten. Male mice at 3 weeks of age with the desired genotype were subjected to 
intraperitoneal injections of tamoxifen suspended in corn oil (0.1 ml of 10 mg/ml 4-
hydroxytamoxifen, Sigma) daily for 5 days to induce a gene knockout specific to dermal 
fibroblasts (Pten-/-). Control mice were also generated by injecting a cohort of Ptenfl/fl 
mice with only corn oil, the vehicle for the tamoxifen. Mice required 60 days following 
tamoxifen treatment to develop a fibrotic phenotype. 
2.7 Tumor studies 
B16F10 murine melanoma cells (ATCC) were cultured in the same high glucose 
DMEM medium with 10% FBS, and 1% antibiotic/antimycotic solution as described in 
section 2.1, detached using 0.25% trypsin/0.02% EDTA solution, and resuspended in the 
same low glucose DMEM, serum-free, and with 1% antibiotic/antimycotic solution as 
described in section 2.1 at a density of 3300 cells/µl. Injection of 330,000 cells 
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subcutaneously into the right flank of each C57BL/6J mouse (Jackson Laboratory) was 
performed 60 days post tamoxifen injection date. Once a palpable tumor was detected, 
tumor volume measurements were obtained for all mice for 14 days using a digital caliper 
and the following equation: Tumor Volume (mm3) = 1/2(Length of Longest Tumor 
Dimension) x (Length of Narrowest Tumor Dimension)2. After 14 days, the mice were 
sacrificed, administering heparin before ketamine overdose and cervical dislocation. All 
animal protocols were approved by the animal care committee at the University of 
Western Ontario. Post-euthanasia, the lungs were flushed with PBS and then inflated by 
administering 4% paraformaldehyde (PFA) through the trachea. Lung, tumor with 
surrounding skin, and normal skin from the left flank were harvested and fixed in 4% 
paraformaldehyde dissolved in PBS (PFA) for 24 hours. Afterwards, tissues were sent to 
Robarts Research Institute in 70% ethanol to be processed. Tissues were then embedded 
in paraffin, sectioned at 5 µm on a microtome and collected on Superfrost Plus (Fisher 
Scientific) slides. 
2.8 Skin thickness and lung metastasis analysis 
Lung and skin sections were dewaxed in xylene and rehydrated in four descending 
concentrations of ethanol (100%, 95%, 80%, 70%), stained with hematoxylin for 1 min 
and eosin-y for 7 min. Bright-field images of skin were obtained at 3 varying depths 
through the tissue. Skin thickness was then measured using Eclipse software at 6 points 
along the skin, from the surface of the epidermis down to the bottom of the dermis, for all 
3 depths. Lung sections were imaged, and the area of dense purple metastatic foci was 
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assessed as the percentage of the total area of the lung using imageJ software. The two 
groups were then compared using an unpaired T-test, and significance was set at P<0.05. 
2.9 Tissue homogenization 
Skin tissues harvested from the opposite flank of the injected tumor were placed 
inside prefilled zirconium bead microtubes (MIDSCI Cat#D1032-30) along with 1 ml of 
Trizol. The tissues were then homogenized using a Beadbug Microtube Homogenizer 
(MIDSCI Cat#D1030) for 3 individual basic cycles, or until the tissues were completely 
homogenized. The Trizol was then transferred to a separate tube where RNA was 
extracted as described in section 2.2. 
2.10 Immunocytochemistry analysis 
A 24-well plate with glass slide inserts was coated with 500µl of collagen type 1 
bovine overnight (10µg/ml) (Invitrogen Cat#A1064401). HFFs were then plated (8000 
cells/well) and allowed to attach overnight. Cells were then serum starved and treated 
with VP or DMSO ± TGFβ as described in section 2.1 for 24 hours, administering 
TGFβ1 30 min after VP. Cells were fixed in 4% paraformaldehyde (Sigma), washed in 
PBS two times for 2 minutes each, and blocked for 45 minutes in a solution containing 
0.1% TritonX-100 in PBS and 10% donkey serum (Jackson Immunoresearch, West 
Grove, PA, USA). Cells were then incubated with rhodamine-conjugated phalloidin 
(ThermoFisher #R415) diluted 1:1000 in blocking solution for 45 min in the dark. After 
washing in PBS two times for 2 minutes, the glass slides were mounted on coverslips 
using DAPI fluorescent mounting medium (Vectashield #H-1200). Fluorescence images 
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were acquired with a Zeiss Imager M1 fluorescence microscope (Toronto, ON, Canada), 
using 360nm to visualize DAPI in blue and 540nm to visualize rho-phalloidin in red. 
Images were overlaid using Northern Eclipse software (Empix, Mississauga, ON, 
Canada). 
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3 Results 
 
3.1 Cell culture-based studies 
 
3.1.1 VP blocks TGFβ1 induced HFF myofibroblast-like phenotype 
As an initial proof-of-concept approach to assess if VP could block profibrotic 
activity of fibroblasts, I examined changes in fibroblast morphology and 
differentiation into myofibroblasts that result in response to treatment with VP and 
TGFβ1. HFFs were treated with VP for 24 hours in the presence or absence of 
TGFβ1. HFFs that were incubated only with TGFβ1 demonstrated increased 
formation of stress fibers consistent with myofibroblast differentiation, as well as 
increased cell growth. HFFs treated VP alone demonstrated seemingly fewer 
formations of stress fibers, and when combined with TGFβ1, completely inhibited the 
ability of TGFβ to induce a myofibroblast-like phenotype in HFFs (Figure 3.1).  
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DMSO 
VP 
TGFβ1 
VP + TGFβ1 
Figure 3.1  VP blocks TGFβ1 induced HFF myofibroblast-like phenotype 
HFFs (passage 10) were plated at approximately 8000 cells/well in a 24-well plate, 
precoated with 10µg/ml collagen on glass slides. Cells were treated with either DMSO or 
VP and ± TGFβ1 in triplicate for 24 hours. Cells were then fixed with 4% PFA and 
blocked in solution and incubated in rho-phalloidin diluted 1:1000 in blocking solution. 
Afterwards slides containing the cells were mounted on larger glass slides with DAPI 
fluorescent mounting media. Images were taken under fluorescent microscopy. An image 
that best represented the average in each condition are provided above. HFFs treated with 
TGFβ1 alone displayed increased cellular growth as well as increased differentiation into 
myofibroblasts, indicated by formation of SMA stress fibers visualized in red. Treatment 
with VP 30 min prior to TGFβ1 completely inhibited this effect (Bar, 100 µm). 
 30 
 
3.1.2 VP significantly inhibits gene expression of CCN2, COL1A1, 
COL1A2, and TGFB1, and does not affect expression of 
PTEN or YAP 
Accumulation of collagen within scar tissue is a characteristic feature of and 
leading contributing factor to pathological fibrosis (Hinz et al., 2012; Borthwick et al., 
2013). Over-secretion of collagen in fibrotic lesions  by myofibroblasts is not induced by 
TGFβ1, at least at the mRNA level (Liu et al., 2014). Therefore, when assessing the 
ability of VPs to inhibit collagen expression, we first determined the effect of VP on gene 
expression in unstimulated cells (fibroblasts treated with DMSO vehicle control). 
Otherwise, VP treatment was administered on HFFs for 6 hours, and a delta-delta CT 
qPCR analysis was performed. Data sets were analyzed using a standard unpaired t-test. 
Baseline expression of CCN2, COL1A1, COL1A2, and TGFB1 were significantly 
inhibited by VP treatment, while expression of PTEN and YAP were not (Figure 3.2). 
VP treatment reduced levels of TGFβ1 mRNA, suggesting the intriguing 
possibility that the inhibition of a fibrotic phenotype in cells treated with VP could be 
caused by an inhibition of TGFβ expression. 
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Figure 3.2 VP significantly inhibits gene expression of CCN2, COL1A1, COL1A2, 
and TGFB1, and does not affect expression of PTEN or YAP   
HFFs were treated with only DMSO or VP for 6 hours and analyzed using qPCR delta-
delta CT analysis. All graphs are plots of mean mRNA fold-change ± standard deviation. 
Means of the two treatment groups were compared using an unpaired t-test (GraphPad 
Prism 8.1). Baseline expression of CCN2, COL1A1, COL1A2, and TGFB1 were inhibited 
by VP treatment, while expression of PTEN and YAP were not. (A) CCN2 (P<0.05) 
(n=16) (B) COL1A1 (P<0.05) (n=16) (C) COL1A2 (P<0.05) (n=16)  (D) TGFB1 
(P<0.05) (n=14) (E) PTEN (P=0.990) (n=8) (F) YAP (P=0.686) (n=10) 
 
  
(E) (F) 
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3.1.3 VP reduces gene expression of clusters heavily enriched in 
ECM secretion and binding in the presence and in the 
absence of exogenous TGFβ1 
 To investigate whether downregulation of pro-fibrotic genes was due to 
inhibition of YAP or to decreased expression of TGFβ1, gene level ANOVA fold-change 
values from the microarray analysis were filtered to identify downregulated (<-1.5-fold 
change) in VP treatments compared with DMSO, as well as VP+TGFβ1 compared with 
TGFβ1 (<-1.5-fold change). The two lists of genes were examined using DAVID’s Gene 
functional annotation tool to give insight on alterations in gene expression induced by VP 
treatment, with and without TGFβ1. Between the two lists of 900+ genes each, 45.4% 
were shared. Both lists contained clusters of genes heavily enriched in ECM secretion 
and binding (Figure 3.3).  
3.1.4 VP reduced 28 potential key regulators of TGFβ1- induced 
myofibroblast differentiation 
To investigate specific gene targets that were upregulated by TGFβ1 and that 
were inhibited by VP, two gene lists were compared. One list contained genes that were 
upregulated by TGFβ1 (> 1.5-fold), and the other contained all the genes that were kept 
at or below baseline expression by VP in the presence of TGFβ1 compared to DMSO 
(<1). On this basis, 28 potential key regulators of myofibroblast differentiation were 
found in both lists. Of these 28 targets, the only targets whose mRNA expression was 
also reduced by VP treatment in the presence of exogenously added TGFβ1 were ENPP1 
and LTBP2 (Figure 3.4).   
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Figure 3.3 VP reduces gene expression of clusters heavily enriched in ECM 
secretion and binding in the presence and in the absence of exogenous TGFβ1. 
Gene expression data obtained by microarray analysis were input into Transcriptome 
Analysis Console and two genes lists were generated. One list contained genes that were 
downregulated by VP compared to DMSO (< -1.5-fold change). The other list contained 
genes that were downregulated by VP in the presence of TGFβ1, compared to TGFβ1 
alone (< -1.5-fold change). (A) When the two lists were compared to each other, 45.4% 
of the genes were in common. (B) The first list of 908 genes downregulated by VP alone 
(< -1.5-fold) were input into DAVID Gene functional annotation tool. Returned clusters 
contained genes heavily enriched in transmembrane, cell adhesion, endoplasmic 
reticulum, secreted/ECM, ECM/collagen organization, cell-cell adhesion, and cell 
migration. (C) The second list of 921 genes downregulated by VP in the presence of 
TGFβ1 compared to TGFβ1 alone expression levels (< -1.5-fold) was input into DAVID 
Gene functional annotation tool. Returned clusters were enriched in clusters consistent 
with the previous list. 
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CDH2 -1.29 
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Figure 3.4 VP reduced 28 potential key regulators of TGFβ1- induced 
myofibroblast differentiation. 
Microarray results were filtered to create lists of genes altered in each treatment. 
(A) A list of genes that were up regulated by TGFβ1 (>1.5-fold) was compared 
to a list of genes in VP+TGFβ1 that were expressed at baseline or below. 
Between these lists, 41 similarities were found, 28 of which were encoding 
genes. (B) A list of these similarities with their fold-change values indicating 
down regulation with VP+TGFβ1 vs. DMSO. (C) The list of 28 genes was input 
into DAVID Gene functional annotation tool. Returned clusters that were most 
enriched, similar to clusters in Figure 3.3, involve the ECM and cell migration. 
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3.1.5 VP fails to inhibit expression of TGFβ2, TNFAIP6, and CCN2 
in the presence of TGFβ1 
To give further insight on VP’s inhibition of myofibroblast differentiation, and to 
assess VP as a potential candidate for therapeutic intervention in fibrosis, more gene lists 
were compared as described previously. One list contained genes that were down 
regulated by VP compared to DMSO (<-1.5-fold change), and the other contained a list 
of genes that were up regulated in VP+TGFβ1 treatment compared to DMSO. Three 
genes were common to both lists: TGFB2, TNFAIP6, and CCN2 (Figure 3.5).  
3.1.6 Exogenous TGFβ1 does not interfere with inhibition of pro-
fibrotic gene expression induced by inhibition of YAP with VP 
To ensure the results from the microarray was not due to deficiency of 
endogenous TGFβ1 induced by treatment with VP, additional trials of VP treatment on 
HFFs were performed both in the presence and absence of exogenous TGFβ1 (1 µg/ml). 
VP treatment ± TGFβ1 was administered on HFFs for 6 hours, and a delta-delta CT 
qPCR analysis was performed. Data sets were analyzed using an ordinary one-way 
ANOVA. Expression of CCN2, FN1, ITGA5, LRP1, and EDN1 were significantly 
inhibited in the presence of VP, irrespective of the presence or absence of exogenous 
TGFβ1 (Figure 3.6). 
In summary, treatment of fibroblasts with VP blocked formation of a fibrosis-like 
phenotype, through reduction in expression of ECM secreting and binding gene clusters, 
irrespective of the presence or absence of endogenous or exogenous TGFβ1.  
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Fold Change 
(VP+TGF-B) 
Gene 
Symbol Description 
1.51 TGFB2 transforming growth factor beta 2 
2.04 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 
2.35 CCN2 cellular communication network factor 2 
(B) 
(A) 
Figure 3.5 VP fails to inhibit expression of TGFβ2, TNFAIP6, and CCN2 in the 
presence of TGFβ1 
Microarray ANOVA results were input into Transcriptome analysis console 4.0.1 and 
filtered to create lists of genes altered in each treatment. (A) A list of 908 genes that 
were downregulated by VP (<-1.5-fold) was compared to a list of 739 genes that were 
upregulated by VP+TGFβ1 compared to DMSO (>1.5-fold). Between these lists, 6 
similarities were found, of which 3 were encoding genes. (B) A list of these genes with 
their fold change values (VP+TGFβ1 vs DMSO).  
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Figure 3.6 Exogenous TGFβ1 does not interfere with inhibition of pro-fibrotic gene 
expression induced by inhibition of YAP with VP 
HFFs were treated with either VP or DMSO ± TGFβ1 (1 µg/ml) for 6 hours and RNA 
was extracted. A SYBR qPCR was performed and analyzed using the delta-delta CT 
method. The mean for each treatment was plotted ± standard deviation. Data sets were 
tested for significance using an ordinary one-way ANOVA (GraphPad Prism 8.1).(A) 
CCN2 (P<0.05) (n=13) (B) CCN1 (P=0.105) (n=7) (C) FN1 (P<0.05) (n=17) (D) aSMA 
(P=0.124) (n=7) (E) ITGA5 test (P<0.05) (n=16)  (F) ITGA11 (P=0.578) (n=5) (G) LRP1 
Gene Symbol Fold Change (Replicated) Fold Change (Microarray) 
TGFβ1 VP VP+TGFβ1 TGFβ1 VP VP+TGFβ1 
CCN2/CTGF 7.07 -3.33 2.54 3.47 -1.74 2.35 
CCN1/CYR61 1.71 -1.801 -1.22 1.32 -1.56 -1.12 
FN1 1.34 -6.45 -4.16 1.08 -2.23 -1.68 
ACTA2/aSMA -1.08 -1.36 -2.55 1.05 -1.09 -1.04 
ITGA5 1.07 -3.15 -2.16 1.13 -2.14 -1.89 
ITGA11 1.72 -1.08 1.02 1.19 -2.32 -1.94 
LRP1 -1.11 -5.62 -7.19 1.12 -1.97 -3.57 
EDN1 7.75 -1.28 3.98 4.67 -1.22 2.27 
POSTN 1.25 -5.29 -3.00 1.03 -2.8 -2.51 
TNC 4.11 1.57 1.28 1.16 -4.15 -3.44 
(I) (J) 
(K) 
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(P<0.05) (n=17) (H) EDN1 (P<0.05) (n=7) (I) POSTN (P<0.05) (n=5) (J) TNC (P=0.062) 
(n=17) (K) A chart comparing the fold change values of the replicated qPCR trials to 
their microarray ANOVA counterparts for validation of gene expression. 
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3.2 in vivo mice studies of fibroblast specific Pten- 
deficiency and melanoma tumor metastasis 
3.2.1 Pten expression in connective ear tissue was significantly 
suppressed in Ptenfl/fl mice administered tamoxifen. 
 Indeed, inhibition of YAP with VP in vitro successfully prevented a fibrotic 
phenotype induced by TGFβ1. To assess the importance of the pro-adhesive signaling 
pathway in vivo, we must first ensure that our fibroblast specific Pten- deficient fibrotic 
mouse model has the correct genotype and phenotype. 
To confirm that Pten was inactivated upon tamoxifen treatment in our mouse 
model of fibrosis, we used ear notches as a tissue source from mice in two Ptenfl/fl groups; 
one group was treated with corn oil (vehicle control) and the other with tamoxifen. DNA 
was extracted from ear tissues, which contained Col1α2-expressing fibroblasts. DNA 
from both groups was amplified using the same Pten primer sets. PCR amplification of 
DNA from Ptenfl/fl mice administered corn oil returned a single band at just above 
1000bp, which is the size for the expected fragment for intact Pten. PCR amplification of 
DNA from Ptenfl/fl mice administered tamoxifen returned two bands, one faint band at 
just above 1000bp and another much stronger band at 450bp, which is the size of the 
expected excised fragment of Pten, indicating a successful inactivation of Pten in Col1α2 
expressing fibroblasts (Figure 3.7). Hereafter, the two groups will be termed Ptenfl/fl, 
indicating the group of mice treated only with corn oil; and Pten-/-, indicating the group 
of mice that received tamoxifen.  
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fl/fl Pten (+1000 bp) 
-/- Pten (~450 bp) 500 bp - 
1000 bp - 
Pten
fl/fl
 
+ 
corn oil 
Pten
fl/fl
 
+ 
tamoxifen 
Figure 3.7 Pten expression in connective ear tissue was significantly suppressed in Ptenfl/fl 
mice administered tamoxifen. 
Suppression of Pten was supported using DNA extracted from ear notches. Post tamoxifen 
injections, ear notches were taken, and DNA was extracted.  DNA from the ear notches reflects 
mostly fibroblasts, but also other cell types (for e.g., epithelial cells). The DNA was primed for 
Pten using the same primer for both groups and amplified in a PCR. Amplicons were resolved on 
a 1% agarose gel and visualized with ethidium bromide. Ptenfl/fl + corn oil produced amplicons 
just above 1000kb, the expected size for floxed Pten. Ptenfl/fl + tamoxifen produced strong bands 
at around 450kb, the expected size for the broken fragment of Pten, as well as faint bands at just 
above 1000kb, intact Pten (n=3). 
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3.2.2 Pten expression in skin of Pten-/- mice is decreased, albeit 
non-significant 
To further support the suppression of Pten gene transcription, skin tissue from 
Ptenfl/fl and Pten-/- was homogenized, and RNA was extracted using the TRIzol method. 
Later, cDNA was synthesized and primed for murine Pten primers in a SYBR qPCR. 
Delta -delta CT analysis showed a decrease, albeit non-significant, in the amount of Pten 
mRNA in the Pten-/- group compared to Ptenfl/fl (Figure 3.8). This result may have 
achieved significance if a larger sample size was used. 
3.2.3 Skin in Pten-deficient mice was significantly thicker 
To support the desired phenotype was acquired by the Pten-/- group in our fibrotic 
mouse model, skin sections from both groups were analyzed using H&E staining. Skin 
thickness was quantified by measuring the distance from the epidermis to the bottom of 
the dermal layer. Measurements were taken for each subject at six points along the image 
and repeated for two additional skin sections per subject. Measurements were averaged, 
and the two groups were compared using a standard t-test. Dermal thickness was 
significantly greater in the Pten-/- group compared to Ptenfl/fl mice, consistent with the 
notion that tamoxifen administration induced fibrosis in our model (Figure 3.9). 
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Figure 3.8 Pten expression in skin of Pten-/- mice is decreased, albeit non-significant. 
Skin tissue from both groups was homogenized in microtubes with TRIzol and zirconium 
beads. RNA was then extracted using chloroform/TRIzol and amplified into cDNA. 
Delta-delta CT analysis using Ptenfl/fl as a control yielded fold-changes that show a trend 
towards significant reduction of Pten expressed RNA in Pten-/- group, analyzed using a 
standard unpaired t-test (GraphPad Prism 8.1) (P=0.079) (n=3). Plots are mean mRNA 
fold-change ± standard deviation. Pten-/- had 4.27-fold less Pten mRNA compared to 
Ptenfl/fl. 
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Figure 3.9 Pten-/- had significantly increased dermal thickness compared to Ptenfl/fl. 
Skin sections from both groups were stained with hematoxylin and eosin-y (H&E) and 
visualized under bright-field microscopy. Dermal thickness was measured from the top of 
the epidermis to the top of the adipose layer for both groups using ImageJ software. Data 
set was tested for a normal distribution using a Shapiro-Wilk test. Thickness mean of 
both groups were compared using a standard unpaired t-test and plotted ± standard 
deviation. The dermal thickness was significantly greater in the Pten-/- compared to Pten 
fl/fl (P=0.0083) (n=3) Bar, 250 µm. 
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3.2.4 Ptenfl/fl and Pten-/- mice had no significant difference in 
melanoma primary tumor growth 
To assess the effects of a fibrotic environment on melanoma metastasis, we first 
assessed whether there were differences in tumor growth. Increases in the size of the 
primary tumor were monitored through a two-week period using digital calipers and an 
ellipsoidal equation was used to estimate tumor volumes. Over the entire period of tumor 
growth, there was no significant difference in tumor volume between Ptenfl/fl and Pten-/- 
(Figure 3.10). 
3.2.5 Melanoma lung tumor metastasis in Pten-/- mice  
Based on previous results, it appears that Pten-/- mice exhibit a pro-fibrotic dermal 
phenotype, as reported by others (Parapuram et al., 2011, 2014; Liu et al., 2013 b). It was 
also predicted that melanoma metastasis might be more prevalent in a fibrotic 
microenvironment. To assess this, lung sections from both groups were stained with 
hematoxylin and eosin to visualize the presence of dark purple metastatic foci, indicated 
by the red arrows (Figure 3.11). Visual inspection suggested the presence of more 
metastatic lesions in Pten-/-, but due to the low animal numbers, there was no significant 
difference detected between the groups.  
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Figure 3.10 Ptenfl/fl and Pten-/- had no significant difference in primary tumor 
growth. 
Syngeneic B16F10 murine melanoma cells (330,000) were injected subcutaneously in the 
right flank of either Ptenfl/fl or Pten-/- C57BL/6 mice 60 days after being administered 
corn oil or tamoxifen respectively. On detection of a palpable tumor, volume 
measurements using calipers were taken daily for 14 days. Following this the mice were 
sacrificed via ketamine overdose and cervical dislocation. Means of tumor sizes were 
plotted ± standard deviation and compared at each time point between Ptenfl/fl and Pten-/- 
mice, and no significant difference was found between them at each time point using a 
Mann-Whitney test (P=0.264). 
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Figure 3.11 Pten-/- mice suggest enhanced melanoma tumor metastasis from primary 
tumor to the lungs, however there was no significant difference. 
Sections were stained with hematoxylin and eosin-y (H&E) and visualized under bright-
field microscopy. The images of the entire lung sections were taken and the percent area 
that metastases take up was measured using imageJ software. Means for the two groups 
are plotted ± standard deviation and are presented as a fraction of metastasis area/lung 
area (mm3), compared using an unpaired standard t-test (P=0.081) (n=3) Bar, 125 µm.  
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4 Discussion 
4.1 Clinical relevance 
Fibrosis is a phenotype seen in many different diseases, with no treatment available 
on the market. Almost every organ in the body can undergo physiologic and pathologic 
fibrotic reactions. The problem arises when normal tissue repair becomes unregulated and 
disrupts tissue homeostasis. This excess deposition of ECM components ultimately leads 
to failure of the afflicted organ, involved with 45% of the mortality rates in the Western 
hemisphere (Wynn, 2008; Rosenbloom et al., 2010). Furthermore, fibrosis may also 
cause mortality through exacerbation of other diseases, such as the metastasis of cancer, 
although further investigation in this interaction is required. The key effector cell of 
fibrosis, the myofibroblast, is irreversibly differentiated from fibroblasts and 
continuously secretes pro-fibrotic proteins and ECM components that stiffen the ECM 
and stimulates further differentiation of local cells into myofibroblasts (Gabbiani, 2003; 
Leask et al., 2014; Hutchenreuther et al., 2016). This positive feedback loop seen in 
pathological fibrosis has no cure and intervention of this process would provide a large 
therapeutic benefit to many diseases. 
ECM stiffness seen in fibrotic disease can influence gene transcription in a process 
known as mechanotransduction. Pro-fibrotic ECM components bind to mechanosensitive 
integrin receptors and translate mechanical tension on the cell surface into nuclear 
signaling to alter gene expression and drive myofibroblast differentiation (Zhou et al., 
2010). The nuclear effector of this pathway is YAP/TAZ, a heterodimer that activates the 
TEAD. Persistent activation and differentiation of myofibroblasts is a key characteristic 
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of fibrosis (Gabbiani, 2003; Lagares et al., 2012; Hutchenreuther et al., 2016), which is 
perpetuated by heightened integrin-mediated mechanotransduction in a stiff ECM 
environment (Asano et al., 2006; Carracedo et al., 2010; Zhou et al., 2010).  This 
mechanotransduction has been shown to be mediated by YAP (Liu et al., 2015), therefore 
interruption of mechanotransduction may provide therapeutic benefit in fibrotic disease. 
 VP is a drug already approved for macular degeneration. If VP can disrupt 
pathological fibrosis through inhibition of YAP, then cross-purposing this drug could be 
used to treat a large variety of disease without the need for clinical trials. Drug discovery 
for a specific molecular target is a long development process that involves trial and error 
and significant investment. Furthermore, completion of clinical trials for a compound can 
be an almost decade-long process with even more capital investment. Circumventing this 
process by cross-purposing VP for fibrotic treatment could provide a large therapeutic 
benefit with very little investment. 
4.2 YAP activation occurs in response to 
mechanotransduction in otherwise unstimulated 
fibroblasts 
As expected, TGFβ1 alone induced a myofibroblast-like phenotype, characterized by 
increased focal adhesions and actin stress fiber formation. Treatment with VP completely 
inhibited this effect (Figure 3.1). Interestingly, SMA fiber recruitment seen in the TGFβ1 
treatment was not reflected by changes in mRNA (Figure 3.6). Given SMA’s previously 
shown requirement of matrix stiffness (Arora et al., 1994), it is likely that SMA 
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expression was not induced due to a lack of a matrix substrate in our cell culture 
conditions. The SMA fibers induced by TGFβ1 (Figure 3.1) likely arose as a 
consequence of formation of FAs, but without changes in α-SMA mRNA expression.  
To give insight into how VP blocks a TGFβ1 induced myofibroblast-like phenotype, 
changes in gene transcription induced by VP both in the presence and absence of TGFβ1 
were analyzed. Two list of genes downregulated by VP, one with and one without 
TGFβ1, were compared to each other, in addition to being input into a DAVID cluster 
analysis (Figure 3.3). It seems VP could potentially block TGFβ induced myofibroblast 
differentiation through inhibition of genes whose expression positively influences ECM 
modulation, and cell binding to other cells and the ECM. However it is unknown which 
of these genes were directly influenced by TGFβ1 to elicit this response. VP inhibition of 
fibrotic gene clusters in the absence of TGFβ1 compared to baseline tells us in normal 
conditions, there is a baseline expression of fibrotic gene clusters, which is inhibited by 
VP. If VP blocks activation of YAP mechanotransduction which is required for basal 
expression of pro-fibrotic genes, then YAP activation may be required for the ability of 
TGFβ1 signalling to induce gene expression. 
4.3 Significant reduction of LTBP2 and FN1 prevent 
myofibroblast differentiation 
To investigate specific gene targets that were induced by TGFβ1 and affected by 
YAP inhibition, genes that were upregulated by TGFβ1 were compared to genes VP kept 
at baseline or below in the presence of TGFβ (Figure 3.4).  DAVID cluster analysis of 
these 28 genes returned gene clusters that modulate the ECM, like clusters found 
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previously (Figure 3.3).  One of the most inhibited genes, latent transforming growth 
factor-β binding protein 2 (LTBP2), has recently had its protein product become a clinical 
biomarker for IPF progression, which also reflects the level of differentiation of lung 
fibroblasts into myofibroblasts (Enomoto et al., 2018). LTBP2 has been shown to interact 
with FN1, more specifically LTBP2 failed to integrate into the ECM in the absence of 
FN1 (Vehvilainen et al., 2009). FN1 was significantly inhibited by VP both in the 
presence and absence of TGFβ1 (Figure 3.6). Thus, it is possible that VP prevents a 
TGFβ1 induced HFF myofibroblast-like phenotype through reduction of both LTBP2 and 
FN1 mRNA expression, compromising ECM stability and subsequent reduction in 
mechanotransduction.  
4.4 YAP selectively regulates various key pro-fibrotic 
genes 
Various pro-fibrotic gene targets were selected to be analyzed through qPCR analysis. 
This served to replicate the results from the microarray ANOVA for validation (Figure 
3.6). The selection of these important pro-fibrotic gene targets was based on previous 
research in the field.  
A biomarker of progressive fibrosis in SSc (Sato et al., 2000; Leask et al., 2009; 
Morales et al., 2013; Dorn et al., 2018), CCN2 is induced by TGFβ1 signaling and 
reduced by treatment with VP. CCN1, another matricellular protein, known for its 
involvement in angiogenesis, inflammation, and wound repair, has also been shown to 
enhance TGFβ1/SMAD3 signaling and contribute to the fibrogenic response (Kurundkar 
et al., 2016). Here, CCN1 is not significantly affected by either TGFβ1 or VP. Both 
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CCN1 and CCN2 are thought to be downstream of YAP signaling in basal cell carcinoma 
(Quan et al., 2014). Here it seems that although CCN2 is reduced through VP inhibition 
of YAP, it is not completely inhibited by it. This is possibly due to the very low level of 
basal expression of CCN2 in normal, resting fibroblasts, skewing the relative expression 
of VP +TGFβ1 compared to DMSO. In Figure 3.6, CCN2 expression was not 
significantly increased by VP +TGFβ1 compared to DMSO.  
Fibronectin (FN1) is a fibrillar protein that gives stiffness to the ECM and binds with 
integrins to transmit mechanical tension from the ECM through the cell’s cytoskeleton, 
αSMA (Cao et al., 2017). FN1 inhibition has also been shown to reduced collagen 
expression and improve liver function in liver fibrosis (Altrock et al., 2015). FN1 
expression was significantly inhibited by VP both in the presence and absence of TGFβ1, 
however SMA was unaffected. Recent findings have shown that α-SMA mRNA 
expression is induced by matrix stiffness (Avery et al., 2018).  
Integrins, as discussed previously, are the membrane bound receptor that interact with 
fibronectin, collagen, CCN2, and other ECM substrates to form focal adhesions and 
transmit mechanical tension from the ECM through the cellular cytoskeleton. 
Heterodimers of integrins α5β1 bind to fibronectin, collagen and laminin (Chen et al., 
2016 a). Heterodimer α11β1 binds to collagen and α11 transcription has been shown to be 
increased by TGFβ1 signaling in fibrosarcoma cell line as well as in primary fibroblasts 
(Lu et al., 2010). Here, both integrin subunits α5 and α11 are shown to be unaffected in the 
presence of VP and TGFβ1 
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Low-density lipoprotein receptor-related protein 1 (LRP1) is a receptor that has been 
shown to be involved with signal transmission and endocytosis. More importantly, recent 
studies have shown LRP1 to mediate transcytosis of CCN2 in chondrocytes (Kawata et 
al., 2012). Furthermore, a smooth muscle cell targeted gene deletion of LRP1 in mice 
(smLRP1-/-) resulted in protection of vasculature through mediation of the ECM. More 
specifically, smLRP1-/- mice showed increased protein levels of collagen and CCN2 in 
the ECM compared to smLRP+/+ (Muratoglu et al., 2013). In myofibroblasts, production 
of microvesicles (MV) are stimulated by serum. Inhibition of LRP1 in myofibroblasts 
resulted in a significant reduction in MV secretion (Laberge et al., 2018). In HFFs, 
inhibition of YAP by VP significantly inhibited expression of LRP1 both in the presence 
and absence of TGFβ1. It’s possible that excretion of CCN2 and other pro-fibrotic 
proteins into the ECM through MVs could be reduced through VP inhibition of LRP1. 
 Endothelin-1 (EDN1), one of the three human isoforms typically involved with 
vasoconstriction, may also play a role in fibrogenesis. Inhibition of the highly specific 
EDN1 receptor A (ETA) decreased collagen deposition and improved lung function in 
bleomycin-induced lung fibrosis in mice (Manitsopoulos et al., 2018). As previously 
mentioned, TGFβ1 induces endothelial-to-mesenchymal transition (EndoMT), providing 
a source of activated myofibroblasts. EDN1 has been shown to potentiate EndoMT while 
also inducing expression of TGFβ receptor 1 and 2 genes, suggesting a possible autocrine 
mechanism of TGFβ1 induced fibrogenesis (Wermuth et al., 2016). In HFFs, TGFβ1 
significantly induced EDN1 expression, which was significantly reduced but not inhibited 
by VP in the presence of TGFβ1. 
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Periostin (POSTN) is a secreted matricellular protein first found in epithelial ovarian 
carcinoma, acting as a ligand on integrins αVβ3 and αVβ5, promoting cell motility (Gillan 
et al., 2002). Our previous findings show that CCN2-deficient B16(F10) melanoma cells 
demonstrated decreased expression of periostin and decreased the cell’s ability to migrate 
through collagen. This was also reflected in vivo, where CCN2-deficient mice 
demonstrated a loss of periostin and coincided with decreased metastases of melanoma 
from the skin to the lungs (Hutchenreuther et al., 2015). With treatment of VP on HFFs, 
expression of periostin is significantly inhibited in both the presence and absence of 
TGFβ. 
Tenascin-C (TNC) is an ECM glycoprotein which is expressed rapidly in kidney 
fibrotic lesions. The mitogenic activity of TNC has also been shown to require the 
integrin-FAK signaling pathway (Fu et al., 2017). TNC was also identified as a promoter 
of lung adenocarcinoma metastasis (Gocheva et al., 2017). Treatment with VP on HFFs 
significantly inhibited TNC expression from TGFβ1 induced expression levels, both in 
the presence and absence of TGFβ1. 
Most importantly, expression of collagen type 1 alpha 1 and 2 were significantly 
inhibited by VP. Excess deposition of collagen into the ECM is a hallmark of fibrotic 
disease (Gabbiani, 2003; Wynn, 2008). Administering VP to patients with SSc or other 
fibrotic diseases may provide therapeutic benefit through reduction of collagen 
expression.  
Thus, inhibition of YAP-regulated mechanotransduction with VP has elucidated the 
regulation of many important pro-fibrotic targets that all may play a part in influencing 
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ECM stiffness. However, it is unclear how much impact each specific target has. It is 
most likely that all the affected targets contribute to the fibrotic phenotype in some way, 
and that future analysis of ECM modulation should incorporate a multitude of targets. 
4.5 Validation of in vivo fibrotic genotype 
The genotype of our in vivo mouse model of progressive fibrosis was first assessed by 
extracting DNA from ear notches taken post tamoxifen injections. Extracted DNA from 
both conditions were primed using the same Pten primer, performed in parallel. Bands 
from Ptenfl/fl were intact, while bands from Pten-/- included both intact and fragmented 
Pten. The ear notch tissue used to extract DNA contains mainly fibroblasts, but also other 
cell types, which may explain the presence of the intact band since our KO model is 
targeted towards fibroblasts exclusively. However, this discrepancy may also be due to 
the tamoxifen-induced gene KO not being 100% efficient. Later, skin was homogenized, 
and this time extracted RNA was primed for Pten. Delta-delta CT analysis of the qPCR 
showed a trend towards decrease in Pten mRNA, Pten-/- skin had 4.27-fold less Pten 
mRNA than the control group. As before, these results do not reflect only fibroblast 
cultures, but other cell types as well. Regardless, the Pten-/- group is verified to have the 
intended genotype. 
4.6 Loss of fibrotic phenotype 
 Previously this progressive fibrotic model targeting Pten has increased dermal 
thickness 3-fold (Parapuram et al., 2011). However, the mean fold-change of the Pten-/- 
group’s dermal thickness compared to the mean of Ptenfl/fl was only 1.25-fold greater 
than the control group. Even more interestingly, our progressive model was given more 
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time to progress compared to previous trials, 60 days compared to 45 days. The 
phenotype of our Pten-/- skin was not as fibrotic as it should be, even though the mice had 
the desired genotype. Our colonies of mice were bred for over 10 generations, therefore 
one reasonable explanation for this discrepancy could be genetic drift, the accumulation 
of random mutations in the colony. Some of these mutations may affect the desired 
phenotype, which would help to explain the large variability in the skin adipose layer and 
dermal layer’s thickness, as well as the underwhelming increase in skin thickness in Pten-
/-. It is reasonable to expect that the reduced impact on skin thickness would reduce any 
expected impact on increasing melanoma metastasis. 
4.7 Limitations 
Previous analysis of filtered gene lists from the microarray ANOVA were generated 
with the criteria that the gene targets were induced by TGFβ1 by at least 1.5-fold. It is 
possible that key gene targets regulated by YAP are not induced by TGFβ1 significantly 
enough to reach the set threshold and may have been excluded in the analysis. One 
example is FN1, which was not induced enough to be included in Figure 3.4 alongside 
LTBP2. Furthermore, DAVID gene clusters analysis performed well to divide the list of 
genes into functional groups but is not ideal for functional classification of relatively 
unknown gene targets. Most notably FN1 and COL1A1 were lacking from notable 
fibrotic gene clusters.  
Also, it is worth considering the possible inefficiency of VP as an inhibitor of YAP. 
The lack of inhibition of various pro-fibrotic gene target expression (Figure 3.5) could be 
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due to incomplete inactivation of YAP. Another recent study concluded that VP did not 
seem ideal as an pharmacological inhibitor of YAP-TEAD (Gibault et al., 2016).  
Finally, the relatively small sample size for multiple experiments severely limited the 
analysis for multiple experiments. All the in vivo experiments had a relatively sample size 
(n=3), and results such as Figure 3.8 and 3.11 could have achieved significance if a 
larger sample size was used. The sample size for the microarray was also low (n=2). 
Changes in the transcriptome may not accurately represent average changes in the 
transcriptome for all HFFs. This may describe the small discrepancies in fold-change 
values between the microarray and replicated trials in Figure 3.6. 
4.8 Future experiments 
  After comparing the average area melanoma metastasis occupies of the lung, it 
was revealed there was no significant difference between the two, however our results 
suggest that there might be an increase and a larger number of N values might uncover 
this fact. To determine the required group size to achieve a significant difference, a power 
analysis was performed using G*Power 3 software. To achieve significance, three more 
replicates with similar results per group would be needed (Figure 4.1). This trend 
combined with the underwhelming effect of Pten suppression on progressive fibrosis can 
supports that further experiments with much larger sample sizes are required to further 
elucidate the effect of a fibrotic microenvironment on cancer metastasis. 
Furthermore, future experiments could verify YAP as a positive mediator of fibrosis 
through a double knockout mouse model of both Pten and Yap. If blocking Yap activity 
rescues the fibrotic phenotype induced by Pten knockout, then it further supports a role  
 61 
 
 
Figure 4.1 Increased mouse group size would be required to be able to accurately 
measure significance. 
G*Power 3.1.9.2 was used to perform a power analysis on a standard two-tailed T-test 
between Ptenfl/fl and Pten-/-. The type of power analysis “A priori” was selected. Effect 
size (d=2.32) was calculated and input using the built-in tool using the means and 
standard deviation of lung metastasis area for both groups. Values for α and Power were 
P=0.05 and P=0.95 respectively, with an allocation ratio N2/N1=1. Output results yielded 
required sample size to achieve desired P=0.95 would require three more animal subjects 
per group, for a total n=12. 
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for YAP as a key regulator of fibrogenesis. Alternatively, VP could be administered in 
drug form along with bleomycin or a Pten-/- mouse model to see if Yap inhibition with 
VP could prevent induced fibrosis. 
Further analysis of YAP activation as a pro-mediator of fibrotic gene transcription 
should also be performed. Specifically, analysis of gene expression profiles induced by 
inhibition of YAP could be investigated using tools such as IBM’s Watson machine 
learning, or artificial intelligence (AI). Advanced mass-data analysis looking for patterns 
in data or literature could provide insights into modulation of the ECM in fibrotic disease 
that humans can’t perceive (Chen et al., 2016 b). 
4.9 Conclusion 
Here we confirm our hypothesis that VP inhibition of YAP reduces expression of 
fibrogenic gene clusters. Furthermore, VP treatment completely inhibited a TGFβ1-
induced fibrosis-like phenotype in HFFs. Investigation using microarray analysis 
elucidated LTBP2 expression  reduced by YAP inhibition both in the presence and 
absence of exogenous TGFβ1 and perhaps a key mediator of ECM induced fibroblast 
activation. Induced progressive fibrosis in vivo using Pten-deficient mice didn’t induce 
the fibrotic phenotype or exacerbate melanoma tumor metastasis as expected, however 
due to the lackluster fibrotic phenotype we induced, further trials should be completed. A 
more recent study has shown YAP/TAZ activation as a key target for metastatic cancer 
(Warren et al., 2018). Perhaps YAP activation in myofibroblast differentiation, 
profibrotic gene expression, and cancer metastasis are all linked through increased 
mechanotransduction in a fibrotic microenvironment, thus therapeutic strategies to 
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prevent over-activation of YAP via verteporfin could be beneficial to a multitude of 
diseases.  
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